Test Compendium is your definitive resource for detailed information on a wide array of diagnostic tests. Each entry in our compendium is meticulously cataloged to aid healthcare providers in selecting and interpreting the right tests for their patients.
Displaying 326 - 350 of 352
EGFR Methodology Molecular Test Description Genes EGFR Disease non-small cell lung carcinoma (NSCLC) EGFR encodes a receptor tyrosine kinase involved in cell proliferation and survival. Activating mutations,
KRAS Methodology Molecular Test Description Genes KRAS Disease colorectal, lung, and pancreatic cancers KRAS encodes a GTPase that regulates cell signaling through the MAPK and PI3K pathways. Mutations,
BRAF Methodology Molecular Test Description Genes BRAF Disease melanoma, colorectal, thyroid, and lung cancersBRAF encodes a serine/threonine kinase downstream of RAS in the MAPK pathway. The V600E mutation
NRAS Methodology Molecular Test Description Genes NRAS Disease melanoma & colorectal cancersNRAS encodes a GTP-binding protein that regulates cell proliferation and survival. Mutations in codons 12, 13,
NTRK1/2/3 Methodology Molecular Test Description Genes NTRK1, NTRK2 & NTRK3 Disease All Solid tumorsNTRK1, NTRK2, and NTRK3 encode the tropomyosin receptor kinase (TRK) family of proteins involved in neuronal
OncoSwift® Bladder Comprehensive Methodology Molecular Test Description Genes ALK, AKT1, AR, ATM, BAP1, BRAF, BRCA1, BRCA2, CDKN2A, CCND1, CREBBP, EGFR, ERBB2, ERBB3, ERBB4, FANCA, FBXW7, FGFR1, FGFR2,
OncoSwift® Brain Comprehensive Methodology Molecular Test Description Genes AKT1, APC, ATM, AXIN2, BRAF, CHEK1, CHEK2, ERBB2, ERBB3, ERBB4, EGFR, FANCA, FBXW7, HRAS, KRAS, MAP2K1, MET, MLH1, MSH2, MSH6,
OncoSwift® Breast Comprehensive Methodology Molecular Test Description Genes AR, AKT1, ATM, BRAF, BRCA1, BRCA2, CCNE1, CDH1, CDK12, CHEK1, CHEK2, EGFR, ERBB2, ERBB3, ERBB4, ESR1, FANCA, FANCL, FGFR1,
OncoSwift® Colorectal Comprehensive Methodology Molecular Test Description Genes AKT1, APC, ATM, AXIN2, BRAF, CHEK1, CHEK2, ERBB2, ERBB3, ERBB4, EGFR, FANCA, FBXW7, HRAS, KRAS, MAP2K1, MET, MLH1, MSH2,
OncoSwift® Endometrial Comprehensive Methodology Molecular Test Description Genes AKT1, APC, ARID1A, ARID2, ATM, BRAF, BRCA1, BRCA2, CDK12, CDK4, CHEK2, CTNNB1, EPCAM, ERBB2, ESR1, FBXW7, KRAS, MDM2,
OncoSwift® Esophagus Comprehensive Methodology Molecular Test Description Genes AKT1, AR, ARAF, ARID1A, BRAF, CDK12, CDK6, CCNE1, CCND1, CDKN2A, EGFR, ERBB2, ERBB3, FGFR1, FGFR2, FGFR3, KIT, KRAS, MCL1,
OncoSwift® Gastric/GIST Comprehensive Methodology Molecular Test Description Genes AR, APC, ATM, BRAF, CD274, CDH1, CCNE1, CTNNB1, ERBB2, ERBB4, EGFR, FBXW7.FGFR1, FGFR2, FGFR3, KRAS, MET, MDM2, MEN1,
OncoSwift® Head and Neck Comprehensive Methodology Molecular Test Description Genes AR, ATM, ARAF, BRAF, CD274, CDKN2A, EGFR, ERBB2, ERBB3, FGFR1, FGFR2, FGFR3, HRAS, IDH1, IDH2, KRAS, MET, MTOR, MLH1,
OncoSwift® Liver Comprehensive Methodology Molecular Test Description Genes AKT1, ARAF, ARID1A, ATM, BRAF, BAP1, BRCA1, BRCA2, CTNNB1, EGFR, ERBB2, ERBB3, ERBB4, ESR1, FGFR1, FGFR2, FGFR3, FGFR4, GNA11,
OncoSwift® Lung Comprehensive Methodology Molecular Test Description Genes AKT1, ALK, ARAF, ATM, BRAF, ARID2, CCND1, CD274, CDK4, CDKN2A, CHEK2, ERBB2, ERBB3, EGFR, FGFR1, FGFR2, FGFR3, HRAS, KEAP1,
OncoSwift® Melanoma Comprehensive Methodology Molecular Test Description Genes APC, ARID2, ATM, BRAF, BAP1, BRCA2, CCND1, CDK4, CDKN2A, CHEK2, CTNNB1, EIF1AX, FBXW7, GNA11, GNAQ, GNAS, IDH1, KIT, MAP2K1,
OncoSwift® Ovarian Comprehensive Methodology Molecular Test Description Genes AKT1, ARAF, ATM, ARID1A, BARD1, BRAF, BRCA1, BRCA2, BRIP1, CCNE1, CDK12, CHEK1, CHEK2, CTNNB1, ERBB2, ESR1, FGFR1, FGFR2,
OncoSwift® Pancreas Comprehensive Methodology Molecular Test Description Genes ALK, ATM, BRAF, BRCA1, BRCA2, CDKN2A, ERBB2, FGFR1, FGFR2, FGFR3, FANCL, IDH1, IDH2, KRAS, MLH1, MSH2, MSH6, NRG1, NTRK1,
OncoSwift® Prostate Comprehensive Methodology Molecular Test Description Genes AKT1, AR, ARID1A, ATM, ATR, BARD1, BRAF, BRCA1, BRCA2, BRIP1, CCND1, CDK12, CHEK1, CHEK2, CTNNB1, FANCA, FANCD2, FANCL,
OncoSwift® Thyroid Comprehensive Methodology Molecular Test Description Genes ALK, AKT1, BRAF, BRCA1, BRCA2, CDKN2A, CTNNB1, FGFR1, FGFR2, FGFR3, HRAS, IDH1, IDH2, KRAS, MET, NTRK1, NTRK2, NTRK3, NRAS,
OncoSwift® Tumor of Unknown Origin Comprehensive Methodology Molecular Test Description Genes AKT1, ALK, AR, ARAF, BRAF, CD274, CDK4, CDKN2A, CHEK2, CNNB1, EGFR, ERBB2, ERBB3, ERBB4, ESR1, FGFR1, FGFR2,
BRCA1/BRCA2 Methodology Molecular Test Description Genes BRCA1/2 Disease breast, ovarian, pancreatic, and prostate cancers.The BRCA1 and BRCA2 genes play critical roles in DNA repair through homologous
Lynch Syndrome & Hereditary Colon Cancer Risk Assessment Panel Methodology Molecular Test Description Genes APC, ATM, AXIN2, BRCA1, BRCA2, BARD1, BMPR1A, BRIP1, CDH1, CHEK2, EPCAM, MLH1, MRE11A, MSH2,
Comprehensive Hereditary Panels-Hereditary Breast and Ovarian Cancer Methodology Molecular Test Description Genes ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, MRE11A, MUTYH, NBN, NF1, PALB2, PTEN, RAD50,
Comprehensive Hereditary Panels-Hereditary Pancreatic Cancer Methodology Molecular Test Description Genes APC, ATM, BRCA1, BRCA2, BMPR1A, CDK4, CDKN2A, EPCAM, MEN1, MLH1, MSH2, MSH6, NF1, PALB2, PMS2,
With core values rooted in service and integrity, our leadership team sets the bar high.
We consistently strive to set the model for exactly how a reference laboratory should engage with both physicians and patients.
siParadigm is accredited by CLIA (Clinical Laboratory Improvement Amendments) and certified by CAP (College of American Pathologists).
We also hold select state licensure where required.